NCT00857545
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase II



Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Gynecologic Oncology Group, National Cancer Institute (NCI)
Phase II
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase II
Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence
Conditions: Breast Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I
Vaccine Therapy Plus Biological Therapy in Treating Patients With Relapsed Prostate Cancer
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase II
Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center
Phase I
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase I
Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer
Conditions: Prostate Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase II
Vaccine Therapy in Treating Patients With Breast Cancer
Conditions: Breast Cancer
Sponsors: Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)
Phase II